Prevention of isolation-induced hypertension by intrahippocampal administration of a nonpeptide kappa-opioid receptor agonist - PubMed (original) (raw)
Prevention of isolation-induced hypertension by intrahippocampal administration of a nonpeptide kappa-opioid receptor agonist
R C Wright et al. Hippocampus. 2001.
Abstract
Previous research in this laboratory showed that hypertension in the spontaneous hypertensive rat (SHR) appears to correlate to insufficient production of hippocampal dynorphins, and that blood pressure could be reduced by intrahippocampal administration of dynorphins and nonpeptide kappa agonists. The purpose of the present study was to investigate whether kappa agonists could prevent the development of hypertension in a different hypertensive model, i.e., the isolated male rat model of hypertension (IHR). Isolation of young male rats for 5-7 days in standard rat cages caused an increase in systolic blood pressure from a mean of 132 to 184 mmHg. The blood pressures of rats grouped 3 per cage remained stable. Rats received the nonpeptide kappa agonist U62, 066E, (Spiradoline, Upjohn), 10 nmoles/0.2 microl or drug vehicle bilaterally into the the hippocampus for 3 days prior to and during isolation or grouping. Animals treated with U62, 066E did not develop hypertension as compared to isolated animals treated with vehicle. The isolation procedure used in these studies appears to induce anxietal stress, as indicated by reduced time spent by the rats in the open arms of the elevated-plus maze. This time is increased by U62, 066E, suggesting that the drug possesses anxiolytic properties and may reduce hypertension in part, by blocking an anxiety/stress component. These data strengthen our previous findings that opioids in the hippocampus may be important in restraining increased blood pressure provoked by environmental stimuli such as isolation.
Similar articles
- Hippocampal administration of kappa-opioid receptor antisense exacerbates isolation-induced hypertension.
Wright RC, Ingenito AJ. Wright RC, et al. Neuropeptides. 2000 Dec;34(6):360-7. doi: 10.1054/npep.2000.0839. Neuropeptides. 2000. PMID: 11162293 - Depressor effect of kappa opioid agonist on hypertension induced by isolation in the rat.
Shen S, Ingenito AJ. Shen S, et al. Clin Exp Hypertens. 1999 Apr;21(3):275-97. doi: 10.3109/10641969909068667. Clin Exp Hypertens. 1999. PMID: 10225482 - Blockade of dorsal hippocampal kappa-opioid receptors increases blood pressure in normotensive and isolation-induced hypertensive rats.
Wright RC, Ingenito AJ. Wright RC, et al. Neuropeptides. 2003 Apr;37(2):127-32. doi: 10.1016/s0143-4179(03)00024-6. Neuropeptides. 2003. PMID: 12747945 - Early postnatal stress alters place conditioning to both mu- and kappa-opioid agonists.
Michaels CC, Holtzman SG. Michaels CC, et al. J Pharmacol Exp Ther. 2008 Apr;325(1):313-8. doi: 10.1124/jpet.107.129908. Epub 2008 Jan 18. J Pharmacol Exp Ther. 2008. PMID: 18203949 - Mechanisms involved in the hypotensive effect of a kappa-opioid receptor agonist in hypertensive rats.
Guo HT, Zhang RH, Huang LY, Li J, Liu YL, Bi H, Zhang QY, Wang YM, Sun X, Ma XL, Cheng L, Liu JC, Yu SQ, Yi DH, Pei JM. Guo HT, et al. Arch Med Res. 2007 Oct;38(7):723-9. doi: 10.1016/j.arcmed.2007.04.009. Arch Med Res. 2007. PMID: 17845890
Cited by
- Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.
Crowley NA, Kash TL. Crowley NA, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Oct 1;62:51-60. doi: 10.1016/j.pnpbp.2015.01.001. Epub 2015 Jan 12. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25592680 Free PMC article. Review. - Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone.
Glover EM, Davis M. Glover EM, et al. Psychopharmacology (Berl). 2008 Jun;198(2):167-80. doi: 10.1007/s00213-008-1112-0. Epub 2008 Mar 7. Psychopharmacology (Berl). 2008. PMID: 18324390 - A review of the properties of spiradoline: a potent and selective kappa-opioid receptor agonist.
Wadenberg ML. Wadenberg ML. CNS Drug Rev. 2003 Summer;9(2):187-98. doi: 10.1111/j.1527-3458.2003.tb00248.x. CNS Drug Rev. 2003. PMID: 12847558 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical